The Effect of Intravenous Vitamin C Infusion on Periprocedural Myocardial Injury for Patients Undergoing Elective Percutaneous Coronary Intervention

Wang, Zhi Jian; Hu, Wen; Liu, Yu Yang; Shi, Dong; Cheng, Wan Jun; Guo, Yong; Zhao, Ying; Zhou, Yu Jie

doi:10.1016/j.cjca.2013.08.018

Cited by 38 publications

(53 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, CK‐MB elevation was seen in 4.8% of intervention and 11.4% of control group ( P =.435) as well as the rise of troponin‐I was recognized in 6.8% of control group and in none of the intervention group ( P =.242) . Moreover, in one randomized trial, infusion of 3‐gram vitamin C within 6 hours before elective PCI significantly reduced PMI in vitamin C group as follows: CK‐MB, 4.2% vs 8.6%; P =.035 and troponin‐I, 10.9% vs 18.4%; P =.016 …”

Section: Discussionmentioning

confidence: 55%

“…23 Moreover, in one randomized trial, infusion of 3-gram vitamin C within 6 hours before elective PCI significantly reduced PMI in vitamin C group as follows: CK-MB, 4.2% vs 8.6%; P=.035 and troponin-I, 10.9% vs 18.4%; P=.016. 24 To the best of our knowledge, there is no study investigated the cardioprotective role of CoQ10 following elective PCI. However, sev-…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The randomized clinical trial of coenzyme Q10 for the prevention of periprocedural myocardial injury following elective percutaneous coronary intervention

Aslanabadi

Safaie

Asgharzadeh

et al. 2016

Cardiovascular Therapeutics

View full text Add to dashboard Cite

Introduction:Periprocedural myocardial injury (PMI) following elective percutaneous coronary intervention (PCI) is an important therapeutic concern with remaining some mortality and morbidity. To the best of our knowledge, there is no published study that investigates the potential benefit of CoQ10 in preventing PMI following elective PCI. Methods:In a randomized, clinical trial, 100 patients who scheduled for elective PCI were allocated in to the intervention (n=50) and control group (n=50). The intervention received a 300 mg loading dose CoQ10 12 hours before procedure.The level of CK-MB and troponin-I was measured before procedure, and 8 and 24 hours after. Furthermore, hs-CRP was measured at baseline and 24 hours after.All patients were assessed for the incidence of major adverse cardiac effects (MACEs) after 1 month. Results:The CK-MB elevation (above the upper limit normal) was occurred in 22% (n=11) of CoQ10 and 20% (n=10) of control (P=.806). The elevation of troponin-I was documented in 8% (n=4) of both groups. No significant change in the level of cardiac biomarkers was noted. However, the significant reduction in hs-CRP level was occurred in CoQ10 group (P=.032). Conclusion:The results showed that pretreatment with 300 mg CoQ10 12 hours before procedure could not reduce PMI following elective PCI, however, significantly decreased hs-CRP. K E Y W O R D SCK-MB, CoQ10, hs-CRP, Percutaneous coronary intervention, Periprocedural myocardial injury, Troponin-I

show abstract

Section: Discussionmentioning

confidence: 55%

Section: Discussionmentioning

confidence: 99%

The randomized clinical trial of coenzyme Q10 for the prevention of periprocedural myocardial injury following elective percutaneous coronary intervention

Aslanabadi

Safaie

Asgharzadeh

et al. 2016

Cardiovascular Therapeutics

View full text Add to dashboard Cite

show abstract

“…Moreover, in 1 randomized trial, infusion of 3 g of vitamin C within 6 hours before elective PCI significantly reduced PMI in the vitamin C group (CK‐MB, 4.2% versus 8.6%; P = .035; cTnI, 10.9% versus 18.4%; P = .016) …”

Section: Discussionmentioning

confidence: 93%

“…23 Moreover, in 1 randomized trial, infusion of 3 g of vitamin C within 6 hours before elective PCI significantly reduced PMI in the vitamin C group (CK-MB, 4.2% versus 8.6%; P = .035; cTnI, 10.9% versus 18.4%; P = .016). 24 Recently in 2 randomized trials, we evaluated the effect of 1200 mg pentoxifylline and 300 mg coenzyme Q10 for the prevention of myocardial injury following elective PCI. 25,26 In the first trial, a loading dose of 1200 mg pentoxifylline before elective PCI in 85 patients could not lead to a significant result.…”

Section: Comparison With Other Trialsmentioning

confidence: 99%

Effect of Vitamin D in the Prevention of Myocardial Injury Following Elective Percutaneous Coronary Intervention: A Pilot Randomized Clinical Trial

Aslanabadi

Jafaripor

Sadeghi

et al. 2017

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Myocardial injury following elective percutaneous coronary intervention (PCI) occurs in about one-third of patients and is associated with mortality. Platelet aggregation, thrombosis formation, and inflammation are the main causes of cardiac injury during PCI. Vitamin D plays a key role in the cardiovascular system by exerting antiplatelet, anticoagulant, and anti-inflammatory properties. There is no published study that investigated the effect of vitamin D in the prevention of cardiac injury following elective PCI. In a randomized clinical trial, 99 patients admitted for elective PCI were randomized into vitamin D (n = 52) and control (n = 47) groups. The intervention group received 300 000 IU vitamin D orally 12 hours before PCI. The cardiac biomarkers were checked at baseline, 8 and 24 hours after PCI. hs-CRP was also measured at baseline and after 24 hours. The increase in CK-MB was documented in 20 patients (42%) in the control group and 18 patients (34.6%) in the intervention group (P = .417). Furthermore, the increase in cTnI occurred in 4 patients (8%) and 2 patients (3.3%) in the control and intervention groups, respectively (P = .419). No significant changes were noted in the level of cardiac biomarkers. In the vitamin D group, the mean difference in CK-MB between 8 and 24 hours was significantly lower (P = .048). The mean difference in hs-CRP was significantly lower in the vitamin D group (P = .045). This study could not show a clear effect of vitamin D in the prevention of cardiac injury during elective PCI. Further outcome-based studies are needed to describe the role of vitamin D in the prevention of periprocedural myocardial injury.

show abstract

“…of 50 and 100 mg/kg IV decreased myocardial damage, improved neurological outcome and the survival rate [68,69]. However, using a similar model, Motl and colleagues Wang and colleagues demonstrated that 3g vitamin C IV prior to elective percutaneous coronory reperfusion was associated with less myocardial injury [82]. A metaanalysis, which included 8 randomized controlled trials, demonstrated that vitamin C up to a dose of 2g IV given pre-operatively significantly reduced the risk of atrial fibrillation in…”

mentioning

confidence: 99%

Hydrocortisone, Ascorbic acid and Thiamine (HAT Therapy) for the Treatment of Sepsis. Focus on Ascorbic Acid

Marik¹

2018

Preprint

View full text Add to dashboard Cite

Sepsis is a devastating disease that carries an enormous toll in terms of human suffering and lives lost. Over 100 novel pharmacologic agents which targeted specific molecules or pathways have failed to improve the outcome of sepsis. Preliminary data suggests that the combination of Hydrocortisone, Ascorbic Acid and Thiamine (HAT therapy) may reduce organ failure and mortality in patients with sepsis and septic shock. HAT therapy is based on the concept that a combination of readily available, safe and cheap agents which target multiple components of the host’s response to an infectious agent will synergistically restore the dysregulated immune response and thereby prevent organ failure and death. This paper reviews the rationale for HAT therapy with a focus on vitamin C.

show abstract

The Effect of Intravenous Vitamin C Infusion on Periprocedural Myocardial Injury for Patients Undergoing Elective Percutaneous Coronary Intervention

Cited by 38 publications

References 26 publications

The randomized clinical trial of coenzyme Q10 for the prevention of periprocedural myocardial injury following elective percutaneous coronary intervention

The randomized clinical trial of coenzyme Q10 for the prevention of periprocedural myocardial injury following elective percutaneous coronary intervention

Effect of Vitamin D in the Prevention of Myocardial Injury Following Elective Percutaneous Coronary Intervention: A Pilot Randomized Clinical Trial

Hydrocortisone, Ascorbic acid and Thiamine (HAT Therapy) for the Treatment of Sepsis. Focus on Ascorbic Acid

Contact Info

Product

Resources

About